Acquisition History / ARCHIMED (Essence Parent Inc.) / Esperion Therapeutics, Inc.
ARCHIMED (Essence Parent Inc.) Acquires Esperion Therapeutics, Inc.
Announced May 2026 — $1.10B
What happened
Esperion Therapeutics agreed in May 2026 to be acquired by an affiliate of healthcare investor ARCHIMED and the merger closed July 13, 2026. Aggregate consideration was approximately $1.1B in cash plus contingent value rights entitling holders to up to $100M on specified milestones.
- Acquirer
- ARCHIMED (Essence Parent Inc.)
- Target
- Esperion Therapeutics, Inc.
- Announced
- May 2026
- Price
- $1.10B
- Industry
- Cardiovascular pharmaceuticals
- Buyer type
- Private equity
- Backing investors
- ARCHIMED
- Status
- Closed
By the numbers
Frequently Asked Questions About This Acquisition
When did ARCHIMED (Essence Parent Inc.) acquire Esperion Therapeutics, Inc.?
ARCHIMED (Essence Parent Inc.) acquired Esperion Therapeutics, Inc. on May 2026. This was ARCHIMED (Essence Parent Inc.)'s 1st publicly tracked acquisition out of 1 we have on record.
How much did ARCHIMED (Essence Parent Inc.) pay for Esperion Therapeutics, Inc.?
ARCHIMED (Essence Parent Inc.) paid $1.10B for Esperion Therapeutics, Inc..
What does Esperion Therapeutics, Inc. do?
Esperion Therapeutics agreed in May 2026 to be acquired by an affiliate of healthcare investor ARCHIMED and the merger closed July 13, 2026. Aggregate consideration was approximately $1.1B in cash plus contingent value rights entitling holders to up to $100M on specified milestones.
What other Cardiovascular pharmaceuticals companies has ARCHIMED (Essence Parent Inc.) acquired?
Esperion Therapeutics, Inc. is ARCHIMED (Essence Parent Inc.)'s only publicly tracked acquisition in Cardiovascular pharmaceuticals so far.